-
612-401-D24
DARPP-32 Antibody 100æL
Price: $734.52List Price: $816.13Anti-DARPP-32 (Rabbit) Antibody is suitable for use in ELISA, Western Blotting and IHC. Specific conditions for reactivity should be optimized by the end user. -
612-401-D26
DARPP-32 pS137 Antibody 100æL
Price: $734.52List Price: $816.13Anti-DARPP-32 pS137 Antibody is suitable for use in ELISA and Western Blotting. Specific conditions for reactivity should be optimized by the end user. -
612-401-C73
DARPP-32 pT34 Antibody 100æL
Price: $734.52List Price: $816.13Anti-DARPP-32 pT34 Antibody is suitable for use in ELISA and Western Blotting. Specific conditions for reactivity should be optimized by the end user. -
612-401-D25
DARPP-32 pT75 Antibody 100æL
Price: $734.52List Price: $816.13Anti-DARPP-32 pT75 Antibody is suitable for use in ELISA and Western Blotting. Specific conditions for reactivity should be optimized by the end user. -
30003-13DATA LGR 20MA MODULE W/DSPLY
-
1102590500Analysis Note Appearance - clearness: clear - colour: yellowish-Brown to reddish-Brown pH-value (25 °C): 7.4 - 7.
-
Ab175535-100μgFaricimab (anti-ANG2 &: VEGFA) is a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A). Faricimab (anti-ANG2 &: VEGFA) can be used for diabetic macular edema (DME) research.Purity:≥90%
-
Ab175535-10mgFaricimab (anti-ANG2 &: VEGFA) is a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A). Faricimab (anti-ANG2 &: VEGFA) can be used for diabetic macular edema (DME) research.Purity:≥90%
-
Ab183444-100μgMapatumumab (anti-TNFRSF10A) is a fully human agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab (anti-TNFRSF10A) can be used for the research of
-
Ab183444-10mgMapatumumab (anti-TNFRSF10A) is a fully human agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab (anti-TNFRSF10A) can be used for the research of
-
Ab183444-1mgMapatumumab (anti-TNFRSF10A) is a fully human agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab (anti-TNFRSF10A) can be used for the research of
-
Ab183444-5mgMapatumumab (anti-TNFRSF10A) is a fully human agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab (anti-TNFRSF10A) can be used for the research of